BiotechTube

Xalatan + Travatan Z

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Glaucoma

Conditions

Glaucoma

Trial Timeline

Nov 1, 2008 → Feb 1, 2011

NCT ID
NCT00798694

About Xalatan + Travatan Z

Xalatan + Travatan Z is a approved stage product being developed by Pfizer for Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00798694. Target conditions include Glaucoma.

What happened to similar drugs?

18 of 20 similar drugs in Glaucoma were approved

Approved (18) Terminated (3) Active (1)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
✅Durysta, Bimatoprost Intracameral Implant 10 µgAbbVieApproved
✅Cosopt (combination eyedrop of dorzolamide and timolol)MerckApproved
✅Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension + Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution + Subject's habitual PGA monotherapyNovartisApproved
✅brinzolamide 1%/brimonidine 0.2% fixed combination + Placebo + travoprost 0.004% ophthalmic solutionNovartisApproved
✅Netarsudil ophthalmic solution 0.02% + Artificial tearsNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00798694ApprovedCompleted
NCT00799682ApprovedCompleted

Competing Products

20 competing products in Glaucoma

See all competitors
ProductCompanyStageHype Score
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
40
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
SDP-133 + LumiganSun PharmaceuticalPhase 3
32
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
40
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
39
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
40
Latanoprost + tafluprostSanten PharmaceuticalPre-clinical
26
DE-117B Eye Drops + LatanoprostSanten PharmaceuticalPhase 3
47
DE-104 ophthalmic solution + DE-104 vehicleSanten PharmaceuticalPhase 2
35
DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
40
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-111 ophthalmic solution + Timolol ophthalmic solution 0.5% + Placebo ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicleSanten PharmaceuticalPhase 2
35
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
40
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
40
Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 2/3
38